Central Diabetes Insipidus in a Patient With Lymphoma: A Case Report

Epameinondas Koumpis; Lydia Kyriazopoulou; Stelios Tigas; Eleni Kapsali; Eleftheria Hatzimichael

doi:10.7759/cureus.41500

Central Diabetes Insipidus in a Patient With Lymphoma: A Case Report

Cureus. 2023 Jul 7;15(7):e41500. doi: 10.7759/cureus.41500. eCollection 2023 Jul.

Authors

Epameinondas Koumpis¹, Lydia Kyriazopoulou¹, Stelios Tigas², Eleni Kapsali¹, Eleftheria Hatzimichael¹

Affiliations

¹ Department of Hematology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, GRC.
² Department of Endocrinology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, GRC.

Abstract

Primary central nervous system (CNS) lymphoma or systemic non-Hodgkin lymphoma that infiltrates the CNS can cause central diabetes insipidus (CDI). Polyuria and polydipsia should raise the suspicion of CDI development in patients with lymphoma that infiltrates the CNS. CDI is effectively treated with desmopressin. However, careful monitoring of the patient's serum sodium, fluid intake, urine output, and weight is necessary because patients receiving desmopressin may develop hyponatremia, so they should be alert to recognize this side effect promptly. Moreover, CDI due to lymphoma can occasionally be reversible. Therefore, the dosage of desmopressin should be adapted during or after the treatment of lymphoma.

Keywords: central diabetes insipidus; dlbcl; hypernatremia; lymphoma; neurolymphomatosis.

Publication types

Case Reports